2010年高血压研究领域要点回顾

• 作 者: 郭艺芳
• 机 构: 河北省人民医院心内科,
• 出 处: 中华高血压杂志
• 发表日期: 2010年12期
• 关键词: 高血压研究 奥美沙坦 降压药物 复合终点 非致死性脑卒中 病理生理 钙拮抗剂 群多普利 靶器官保护 那格列奈

2010年即将过去。回顾本年度,对一些新研究结果的争议似乎占据了主旋律。然而恰恰是这些争议,使我们对于高血压的病理生理本质有了更为深入的认识,有力促进了高血压防治策略的进一步完善。1中国高血压防治指南即将更新继2009年我国颁布《中国高血压防治指南(基层版)》之后,预期2010年底《中国高血压防治指南》的修

2010 is about to pass. Looking back this year, the controversy over some of the new findings seems to dominate. However, it is precisely these controversies that give us a deeper understanding of the pathophysiology of hypertension and further promote the improvement of the strategy for prevention and treatment of hypertension. 1 Guide to the Prevention and Treatment of Hypertension in China is about to be updated Following the promulgation of the “Guidelines for Prevention and Control of Hypertension in China (Grassroots Version)” in China in 2009, it is expected that the “Guide to Prevention and Treatment of Hypertension in China” will be revised by the end of 2010